For the Inventor, By the Inventor

Enter assignee name

Dublin, CA, United States of America

Supergen, Inc

USPTO Granted Patents = 52

% Expired Patents = 40.4

CIPO Patents = 1

EPO Patents = 1

Trademarks = 3

Forward Citations = 862

Loading Chart...

Loading Chart...

45 inventors (with patents filed for the assignee):

Joseph Rubinfeld (23 out of 25 patents)

Sanjeev Redkar (15 out of 26 patents)

Ashok Y Gore (15 out of 15 patents)

4. Rajashree Joshi-Hangal (8 out of 16 patents)

5. Hariprasad Vankayalapati (6 out of 51 patents)

6. David J Bearss (6 out of 50 patents)

7. Pasit Phiasivongsa (5 out of 26 patents)

8. Rajesh Shrotriya (5 out of 5 patents)

9. Jorge F DiMartino (4 out of 5 patents)

10. Simeon M Wrenn, Jr (4 out of 4 patents)

11. Yong Xu (3 out of 37 patents)

12. Xichen Zhang (3 out of 3 patents)

13. Stephanie Gong (3 out of 3 patents)

14. Rajashree Joshi (3 out of 3 patents)

15. William Alexander Denny (2 out of 73 patents)

Core Competencies:

Axl Kinase Inhibitors

Quinoline Derivatives

Pharmaceutical Formulations

DNA Methylation

Protein Kinase

Camptothecin

Hematological Disorders

Decitabine

Combination Therapy

Oligonucleotide Analogues

Histone Deacetylase

Paclitaxel

52 patents: Sort by Forward Citations

1. 7998966 - Axl kinase inhibitors (2011-08-16),

2. 7939546 - Quinoline derivatives for modulating DNA methylation (2011-05-10),

3. 7820684 - Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same (2010-10-26),

4. 7790746 - Quinoline derivatives for modulating DNA methylation (2010-09-07),

5. 7750007 - Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitors (2010-07-06),

6. 7700567 - Oligonucleotide analogues incorporating 5-aza-cytosine therein (2010-04-20),

7. 7326712 - Substituted tricyclic compounds as protein kinase inhibitors (2008-02-05),

8. 7276228 - Methods for treating hematological disorders through inhibition of DNA methylation and histone deacetylase (2007-10-02),

9. 7250416 - Azacytosine analogs and derivatives (2007-07-31),

10. 7144873 - Kit for delivering decitabine in vivo (2006-12-05),

11. 7135464 - Method of administering decitabine (2006-11-14),

12. 7071202 - Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor (2006-07-04),

13. 7060290 - Phosphocholine linked prodrug derivatives (2006-06-13),

14. 7049322 - Compositions and formulations of 9-nitrocamptothecin polymorphs and methods of use therefor (2006-05-23),

15. 7037900 - Composition and method for treating graft-versus-host disease (2006-05-02),

Company Overview

Supergen, Inc., based in Dublin, California, specializes in the development of innovative therapies targeting protein kinases, with a focus on Axl kinase inhibitors and quinoline derivatives. The company is dedicated to advancing pharmaceutical formulations aimed at treating hematological disorders, leveraging technologies such as DNA methylation and camptothecin. Through its research, Supergen aims to provide effective solutions for complex medical challenges, contributing to the evolving landscape of targeted cancer therapies.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

52 Patents

#6 in Dublin, CA

#1,588 in California

#6,760 in US

#13,545 in the World

Dublin, CA, United States of America

Supergen, Inc

Forward Citations = 862

45 inventors:

Joseph Rubinfeld (23 out of 25 patents)

Sanjeev Redkar (15 out of 26 patents)

Ashok Y Gore (15 out of 15 patents)

4. Rajashree Joshi-Hangal (8 out of 16 patents)

5. Hariprasad Vankayalapati (6 out of 51 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Supergen, Inc. Retrieved from https://idiyas.com/company/supergen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…